This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
PDS Biotech (PDSB) Up 32% on Interim Data From HPV Cancer Study
by Zacks Equity Research
PDS Biotech's (PDSB) shares gain as it announces encouraging interim data from the VERSATILE-002 study for treating HPV16-positive cancer patients.
Immutep (IMMP) Up on Initial Data From Lung Cancer Study
by Zacks Equity Research
Immutep (IMMP) shares surge on encouraging initial data from a triple combination therapy study, INSIGHT-003, for non-small cell lung cancer.
Mirati's (MRTX) Sitravatinib Fails Lung Cancer Study, Stock Down 8%
by Zacks Equity Research
Mirati Therapeutics' (MRTX) phase III study evaluating sitravatinib as a combination therapy in certain NSCLC patients fails to meet its primary endpoint.
Sarepta (SRPT) Down 11% on FDA Extending DMD Gene Therapy Review
by Zacks Equity Research
The FDA extends the review period for Sarepta's (SRPT) BLA for DMD gene therapy by almost four weeks to Jun 22. The agency may limit the use of the therapy in children aged between four and five.
PTC Therapeutics' (PTCT) Rare Disease Drug Fails in Study
by Zacks Equity Research
PTC Therapeutics' (PTCT) vatiquinone did not achieve its primary endpoint in a late-stage study in treating Friedreich Ataxia patients. Shares decline 21% post the news.
Icosavax (ICVX) Up on Positive VLP Vaccine Candidate Data
by Zacks Equity Research
Icosavax (ICVX) surges on positive data from the clinical study of IVX-A12, targeting respiratory syncytial virus and human metapneumovirus in older adults.
INOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock Up
by Zacks Equity Research
INOVIA (INO) shares surge 12% in the after-market hours, when its drug for treating a rare respiratory tract disease, INO-3107, receives orphan drug designation from the European Commission.
Immunovant (IMVT) Q4 Earnings Top Estimates, Pipeline in Focus
by Zacks Equity Research
Immunovant (IMVT) reports narrower-than-expected results in fourth-quarter fiscal 2023. Pipeline development is on track. Stock surges 12% on Monday.
Alnylam (ALNY) Reports Positive Results From APOLLO-B Study
by Zacks Equity Research
Alnylam (ALNY) announces positive interim analysis results from the phase III APOLLO-B study of patisiran to treat transthyretin-mediated amyloidosis with cardiomyopathy at the end of 18 months.
Moderna (MRNA) Posts Upbeat Data on Protein Replacement Therapy
by Zacks Equity Research
Interim data from a study shows that Moderna's (MRNA) investigational therapy for propionic acidemia (PA) exhibited early signs of dose-dependent pharmacology and potential clinical benefits.
Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now
by Zacks Equity Research
Puma Biotechnology (PBYI), a top-ranked stock, has a promising development candidate, alisertib. Its only marketed product, Nerlynx (neratinib), is witnessing improving demand trends in the United States.
Krystal's (KRYS) Dermatology Drug Gets FDA Nod, Stock Up 10%
by Zacks Equity Research
Krystal's (KRYS) stock soars 10% on Friday after the company announces the FDA approval of Vyjuvek for the treatment of patients six months of age or older with dystrophic epidermolysis bullosa.
PDS Biotech (PDSB) Completes Enrollment for HPV Cancer Study
by Zacks Equity Research
PDS Biotech (PDSB) shares gain as it completes patient enrollment in the second arm of the VERSATILE-002 study for treating HPV16-positive cancer patients.
AbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease
by Zacks Equity Research
AbbVie (ABBV) announces the seventh FDA approval of its JAK inhibitor, Rinvoq, for the treatment of adults with moderately to severely active Crohn's disease.
PTC Therapeutics' (PTCT) PKU Drug Meets Study Goal, Up 7.6%
by Zacks Equity Research
Data from a late-stage study data shows that treatment with PTC Therapeutics' (PTCT) sepiapterin led to a significant reduction in Phe levels in PKU patients. Post the news, share price rises.
MindMed (MNMD) Up on 50% Enrollment in Anxiety Disorder Study
by Zacks Equity Research
MindMed's (MNMD) mid-stage study, evaluating MM-120 for treating general anxiety disorder, reaches over 50% enrollment mark. Its top-line data is expected in late 2023.
Immutep (IMMP) Surges 65% on Upbeat Lung Cancer Study Data
by Zacks Equity Research
A mid-stage study data shows that Immutep's (IMMP) lead candidate as a combination therapy in first-line NSCLC achieved better-than-expected overall survival results.
Ultragenyx's (RARE) GTX-102 Gets FDA Nod for Uniform Dosing
by Zacks Equity Research
Ultragenyx (RARE) stock climbs 5% after the FDA agrees to a protocol amendment to the phase I/II study of GTX-102 in pediatric patients with Angelman syndrome.
Intercept's (ICPT) Liver Drug Combo Gets FDA's Orphan Drug Tag
by Zacks Equity Research
Intercept's (ICPT) fixed-dose combination of obeticholic acid and bezafibrate for the potential treatment of primary biliary cholangitis gets the FDA's Orphan Drug Designation.
PHIO's Skin Cancer Candidate to Enter Clinical Study, Stock Up
by Zacks Equity Research
PHIO surges on the FDA clearance of investigational new drug application for its lead product, PH-762, for the treatment of skin carcinomas.
Bayer's (BAYRY) Arrhythmia Prevention Drug Gets Fast Track Tag
by Zacks Equity Research
Bayer's (BAYRY) oral FXIa inhibitor, asundexian, gets the FDA's Fast Track Designation, as a preventive treatment for stroke and systemic embolism in people with atrial fibrillation.
Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases
by Zacks Equity Research
Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases.
Kodiak's (KOD) Q1 Earnings Miss, Pipeline in Focus, Stock Up
by Zacks Equity Research
Despite poor first-quarter performance, Kodiak (KOD) stock rises 13% on the strong pace of the tarcocimab clinical programs.
ImmunoGen (IMGN) Stock Surges 230% in a Month: Here's Why
by Zacks Equity Research
ImmunoGen (IMGN) shares surge exponentially in the past month owing to the positive data on the expansion study of Elahere for ovarian cancer. An encouraging initial sales uptake of its first marketed product, Elahere, also contribute to the surge.
FDA Rejects ImmunityBio's (IBRX) Bladder Cancer Therapy Filing
by Zacks Equity Research
FDA rejects ImmunityBio's (IBRX) filing seeking approval of Anktiva (N-803) as a combo-therapy in bladder cancer indication, citing deficiencies in an inspection of contract manufacturing firms.